Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio
Albuquerque, NM, February 10, 2025 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI. The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026. These cancer types were strategically selected as the foundation of the macrodissection suite, given that NSCLC, CRC, breast, and prostate cancer collectively represent four of the largest contributors to the burden of cancer, globally.
Understanding a tumor’s genetic makeup is essential for precision medicine and informed treatment decisions. Next-generation sequencing has become the foundation of genetic profiling but requires a tissue specimen to have sufficient tumor content for reliable sequencing results. Unfortunately, the current macrodissection process is tedious, error-prone, lacks auditability, and is highly subjective. The suite of HALO Macrodissection Solutions solves these problems by automatically detecting areas of tumor cells across whole slide images and subsequently generating real-time tumor content calculations that update cumulatively with each region of interest (ROI) selected. This workflow standardizes tumor content results and assists the pathologist in selecting the most concentrated ROI for downstream molecular testing.
“Our rapidly growing portfolio of macrodissection algorithms has been developed to support laboratories as they transition to fully digital, AI-assisted workflows,” said Steven Hashagen, CEO of Indica Labs. “We thoughtfully developed the HALO Macrodissection Solutions suite to address one of the most labor-intensive and variable steps in tissue preparation, delivering reliable downstream molecular testing and confidence in genetic profiling.”
Breast Macrodissect AI seamlessly integrates into HALO AP® enterprise digital pathology platform from Indica Labs and can be paired with Xyall’s Tissector robotic macrodissectors to enable a fully automated and audited macrodissection workflow. This integration improves throughput, and operational efficiency while allowing pathologists to focus on higher-complexity tasks, supported by HALO AP®’s robust capabilities for annotation, collaboration, image analysis, and broad interoperability across scanners, file types, clinical systems, and AI tools.
For more information about Breast Macrodissect AI and additional HALO Macrodissection Solutions, and how these algorithms can enhance efficiency and accuracy in your laboratory, contact info@indicalab.com.
Breast Macrodissect AI is for Research Use Only and not intended for clinical diagnostic use. Breast Macrodissect AI is accessed via the HALO AP® enterprise digital pathology platform.
HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR.
PRR-MAR-000005v1
About Indica Labs:
Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organizations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery.
Media Contact:
Kim Collins
SOURCE: Indica Labs
